-
2024-04-24
PharmaEngine announces first patient dosed in Phase I trial of PEP07 for solid tumor cancers
-
2024-03-24
ONIVYDE® obtains positive opinion from EMA's CHMP for new regimen in First-line Treatment of Metastatic PDAC
-
2024-03-18
ONIVYDE® obtains TFDA Approval for the new regimen in First-line Treatment of Metastatic PDAC
-
2024-02-14
ONIVYDE® obtains U.S. FDA approval of its supplemental new drug application
-
2023-08-15
PharmaEngine announces first patient dosed in Phase I trial of PEP07 for hematological cancers
-
2023-09-22
PharmaEngine announces TFDA approval of PEP07 Phase I clinical trial for solid tumor cancers
-
2023-07-11
PharmaEngine announces EMA's acceptance of ONIVYDE®'s Type II Variation application
-
2023-06-21
PharmaEngine files post-approval change application for a new indication of ONIVYDE® to TFDA
-
2023-06-14
PharmaEngine announces Phase I clinical study of PEP07 has been approved by Taiwan Food and Drug Administration (TFDA)
-
2023-03-03
PharmaEngine announces Phase I clinical study of PEP07 has been approved by Australia HREC and acknowledged by Australia TGA